The endometrial carcinoma market

Nature Reviews Drug Discovery, Published online: 21 January 2022; doi:10.1038/d41573-022-00016-2The endometrial carcinoma market

2d

The endometrial carcinoma market

2d

No shortage of fresh IPO capital in 2021

Nature Reviews Drug Discovery, Published online: 20 January 2022; doi:10.1038/d41573-022-00018-0No shortage of fresh IPO capital in 2021

3d

No shortage of fresh IPO capital in 2021

3d

PROTAC targeted protein degraders: the past is prologue

Nature Reviews Drug Discovery, Published online: 18 January 2022; doi:10.1038/s41573-021-00371-6Targeted protein degradation with proteolysis-targeting chimeras (PROTACs) has the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. This article summarizes the first two...

5d

PROTAC targeted protein degraders: the past is prologue

5d

Biopharma dealmaking in 2021

5d

Biopharma dealmaking in 2021

Nature Reviews Drug Discovery, Published online: 18 January 2022; doi:10.1038/d41573-022-00017-1Biopharma dealmaking in 2021

5d

Immune targets for therapeutic development in depression: towards precision medicine

Nature Reviews Drug Discovery, Published online: 17 January 2022; doi:10.1038/s41573-021-00368-1Accumulating evidence suggests that, for some people, major depressive disorder has immunological roots. Here, Manji and colleagues discuss the progress towards immune-based treatments for depression, including which biomarkers might be most useful, as well...

6d

Immune targets for therapeutic development in depression: towards precision medicine

6d